Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Outline of Final Research Achievements |
We have shown that transcription factor Kruppel-like factor 4 (KLF4) modulates podocyte epigenome and attenuates proteinuria(Hayashi, et al. J Clin Invest. 2014). Moreover, we demonstrated that renin-angiotensin system (RAS) blockade reset podocyte epigenome through KLF4 in part(Hayashi, et al. Kidney Int. 2015). These results provide a new concept that RAS blockade can exert therapeutic effects through epigenetic modulation of the kidney gene expression, and suggest a novel therapeutic approach for treatment of proteinuric kidney diseases.
|